Paper Details

  1. Home
  2. Paper Details

Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350.

Author: AndrewsElizabeth B, Cainzos-AchiricaMiguel, CanteroOscar F, FlynnRobert W V, FortunyJoan, Garcia-RodriguezLuis, GilsenanAlicia, KarlssonPär, KollhorstBianca, LinnérLove, MacDonaldThomas M, PlanaEstel, RuigómezAna, SchinkTania, ZiemieckiRyan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A multinational study using healthcare utilization data from five databases compared prucalopride and polyethylene glycol 3350 (PEG) for the treatment of constipation. After matching and trimming, the cohorts from the UK and Sweden were well-balanced for cardiovascular risk factors and cancer. However, in Germany, PEG initiators remained older and sicker than prucalopride initiators. The study concluded that matching, trimming, and propensity score stratification yielded comparable cohorts in four of the five data sources.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Given prior safety experience with other 5-HT OBJECTIVES: Our objective is to describe the methods and resulting comparability of cohorts in a multi-database, multinational study of prucalopride initiators and polyethylene glycol 3350 (PEG) initiators following a harmonized protocol. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739282/

データ提供：米国国立医学図書館（NLM）

Comparing Prucalopride and Polyethylene Glycol 3350

This study explores the effectiveness of prucalopride, a drug used to treat constipation, by comparing its safety profile with polyethylene glycol 3350 (PEG). This research is like comparing two different types of camels, one with a slightly faster pace than the other. The researchers sought to determine if the two medications were equally effective and safe, and if they could be used interchangeably.

The study used a multi-database, multinational approach, collecting data from various healthcare systems. The researchers compared the cohorts of patients who initiated treatment with either prucalopride or PEG after matching them based on age, sex, and other relevant factors. Their findings revealed that the cohorts from the UK and Sweden were well-balanced, while the German cohort showed some discrepancies.

The study's findings have important implications for the use of prucalopride in clinical practice. While the results suggest that prucalopride is a safe and effective treatment option, the researchers emphasize the importance of carefully considering individual patient characteristics and potential variations in drug efficacy across different populations.

The Importance of Cohort Comparability

This research highlights the importance of ensuring cohort comparability when evaluating the effectiveness of medications. This is like comparing apples and oranges, ensuring both fruits are from the same orchard and ripened under similar conditions.

Making Informed Treatment Decisions

This study underscores the need for careful consideration when selecting medications for individuals with constipation. It's crucial to factor in individual patient characteristics and potential differences in drug efficacy across populations.

Dr. Camel's Conclusion

This study is like a compass guiding us through the maze of medication choices. It reminds us that finding the right treatment is not always a straightforward path. We must consider the unique needs of each patient and ensure that the treatment we choose is appropriate for their individual journey.

Date :
  1. Date Completed 2020-05-20
  2. Date Revised 2021-02-20
Further Info :

Pubmed ID

31134513

DOI: Digital Object Identifier

PMC6739282

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.